SCYNEXIS Receives $7M Grant for Antifungal Therapeutics Development.

SCYNEXIS, a biotechnology company, has received a $7 million annual grant for five years to accelerate the development of new therapeutics for resistant fungal infections. The grant will fund research on next-generation triterpenoid antifungals, which aim to have enhanced pharmacological properties and a broad spectrum of activity against resistant fungal pathogens.